2,4,5-Trisubstituted pyrimidine compounds
0 Assignments
0 Petitions
Accused Products
Abstract
Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
-
Citations
55 Claims
-
1. A compound of the formula
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
2. The compound according to claim 1 wherein R3 is an optionally substituted C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, or aryl.
-
3. The compound according to claim 2 wherein the R3 optional substituents are independently selected from C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylC1-10 alkyl, C5-7 cycloalkenyl, C5-7 cycloalkenyl C1-10 alkyl, halogen, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nNR10S(O)2R7, (CR10R20)nNR4R14, (CR10R20)nCN, (CR10R20)nS(O)2NR4R14, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR4R14, (CR10R20)nNR10C(Z)R6, (CR10R20)nNR10C(═
- NR10)NR4R14, (CR10R20)nOC(Z)NR4R14, (CR10R20)nNR10C(Z)NR4R14, or (CR10R20)nNR10C(Z)OR7;
R4 and R14 are each independently selected from hydrogen, optionally substituted C1-4 alkyl, optionally substituted C3-7 cycloalkyl, C3-7 cycloalkylC1-4alkyl, optionally substituted aryl, or optionally substituted aryl-C1-4 alkyl, or R4 and R14 together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9; R6 is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl C1-10alkyl, aryl, arylC1-10 alkyl, heteroaryl or heteroarylC1-10 alkyl, wherein each of these moieties may be optionally substituted; R7 is a C1-6alkyl, aryl, arylC1-6alkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, or heteroarylC1-6alkyl; and
wherein each of these moieties may be optionally substituted;R9 is hydrogen, C(Z)R6 or optionally substituted C1-10 alkyl, optionally substituted aryl or optionally substituted aryl-C1-4 alkyl; R10 and R20 are independently selected at each occurrence from hydrogen or C1-4alkyl; n is 0 or an integer having a value of 1 to 10; m is 0 or an integer having a value of 1 or 2; and Z is oxygen or sulfur.
- NR10)NR4R14, (CR10R20)nOC(Z)NR4R14, (CR10R20)nNR10C(Z)NR4R14, or (CR10R20)nNR10C(Z)OR7;
-
4. The compound according to claim 3 wherein the R3 optional substituents are independently selected from halogen, alkyl, hydroxy, alkoxy, amino, or halosubstituted alkyl.
-
5. The compound according to claim 1 wherein R3 is a 2,6-difluorophenyl.
-
6. The compound according to claim 1 wherein R1 is an optionally substituted aryl.
-
7. The compound according to claim 6 wherein the R1 aryl is a phenyl optionally substituted one or more times independently by halogen, alkyl, hydroxy, alkoxy, amino, or halosubstituted alkyl.
-
8. The compound according to claim 7 wherein the R1 phenyl is substituted in the 2, 4, or 6-position, di-substituted in the 2,4-position, or tri-substituted in the 2, 4, 6-position.
-
9. The compound according to claim 1 wherein R1 is an optionally substituted phenyl.
-
10. The compound according to claim 1 wherein R1 is a phenyl ring, substituted one or more times independently by halogen, C1-4 alkyl, or halo-substituted-C1-4 alkyl.
-
11. The compound according to claim 1 wherein R1 is 2,4-difluorophenyl, 2-fluorophenyl, 4-fluorophenyl, 2-methyl-4-fluorophenyl, or 2,4,6-trifluorophenyl.
-
12. The compound according to claim 11 wherein R1 is 2-methyl-4-fluorophenyl.
-
13. The compound according to claim 10 wherein the halogen is fluorine, and the C1-4 alkyl is methyl.
-
14. The compound according to claim 1 wherein R12 is a C1-10 alkyl.
-
15. The compound according to claim 1 wherein Rg is methyl.
-
16. The compound according to claim 1 wherein m is 0 or 2.
-
17. The compound according to claim 1 which is (E)-3-[4-(2,6-Difluoro-phenylamino)-6-(4-fluoro-2-methyl-phenyl)-2-methylsulfanyl-pyrimidin-5-yl]-acrylic acid ethyl ester.
-
2. The compound according to claim 1 wherein R3 is an optionally substituted C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, or aryl.
-
18. A compound of the formula
- View Dependent Claims (19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)
-
19. The compound according to claim 18 wherein the R3 ring is optionally substituted one or more times independently by C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylC1-10 alkyl, C5-7 cycloalkenyl, C5-7 cycloalkenyl C1-10 alkyl, halogen, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nNR10S(O)2R7, (CR10R20)nNR4R14, (CR10R20)nCN, (CR10R20)nS(O)2NR4R14, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR4R14, (CR10R20)nNR10C(Z)R6, (CR10R20)nNR10C(═
- NR10)NR4R14, (CR10R20)nOC(Z)NR4R14, (CR10R20)nNR10C(Z)NR4R14, or (CR10R20)nNR10C(Z)OR7; and
R4 and R14 are each independently selected from hydrogen, optionally substituted C1-4 alkyl, optionally substituted C3-7 cycloalkyl, C3-7 cycloalkylC1-4alkyl, optionally substituted aryl, or optionally substituted aryl-C1-4 alkyl, or R4 and R14 together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9; R6 is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl C1-10alkyl, aryl, arylC1-10 alkyl, heteroaryl or heteroarylC1-10 alkyl, wherein each of these moieties may be optionally substituted; R7 is a C1-6alkyl, aryl, arylC1-6alkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, or heteroarylC1-6alkyl; and
wherein each of these moieties may be optionally substituted;R9 is hydrogen, C(Z)R6 or optionally substituted C1-10 alkyl, optionally substituted aryl or optionally substituted aryl-C1-4 alkyl; R10 and R20 are independently selected at each occurrence from hydrogen or C1-4alkyl; n is 0 or an integer having a value of 1 to 10; m is 0 or an integer having a value of 1 or 2; Z is oxygen or sulfur.
- NR10)NR4R14, (CR10R20)nOC(Z)NR4R14, (CR10R20)nNR10C(Z)NR4R14, or (CR10R20)nNR10C(Z)OR7; and
-
20. The compound according to claim 19 wherein the R3 ring is optionally substituted independently by halogen, alkyl, hydroxy, alkoxy, amino, or halosubstituted alkyl.
-
21. The compound according to claim 19 wherein R3 is an optionally substituted aryl.
-
22. The compound according to claim 18 wherein R3 is a phenyl ring, substituted one or more times independently by halogen, C1-4 alkyl, or halo-substituted-C1-4 alkyl.
-
23. The compound according to claim 22 wherein the phenyl is optionally substituted in the 2, 4, or 6-position, di-substituted in the 2,4-position, or tri-substituted in the 2, 4, 6-position.
-
24. The compound according to claim 18 wherein R3 is a 2-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-methyl-4-fluorophenyl, or 2,4,6-trifluorophenyl.
-
25. The compound according to claim 18 wherein R3 is a 2,6-difluorophenyl.
-
26. The compound according to claim 18 wherein R1 is an aryl which is optionally substituted one or more times, independently, by halogen, C1-4 alkyl, halo-substituted-C1-4 alkyl, cyano, nitro, (CR10R20)vNR4R14, (CR10R20)vC(Z)NR4R14, (CR10R20)vC(Z)OR8, (CR10R20)vCORa′
- , (CR10R20)vC(O)H, SR5, S(O)R5, S(O)2R5, (CR10R20)vOR8, ZC(Z)R11, NR10C(Z)R11, or NR10S(O)2R7; and
R4 and R14 are each independently selected from hydrogen, optionally substituted C1-4 alkyl, optionally substituted C3-7 cycloalkyl, C3-7 cycloalkylC1-4alkyl, optionally substituted aryl, or optionally substituted aryl-C1-4 alkyl, or R4 and R14 together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9; R5 is hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR4R14, excluding the moieties SR5 being SNR4R14, S(O)2R5 being SO2H and S(O)R5 being SOH; R6 is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl C1-10alkyl, aryl, arylC1-10 alkyl, heteroaryl or heteroarylC1-10 alkyl, wherein each of these moieties may be optionally substituted; R7 is a C1-6alkyl, aryl, arylC1-6alkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, or heteroarylC1-6alkyl; and
wherein each of these moieties may be optionally substituted;R8 is hydrogen, C1-4 alkyl, halo-substituted C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylC1-4 alkyl, heteroaryl, heteroarylC1-4 alkyl, heterocyclyl, heterocyclylC1-4 alkyl, (CR10R20)tOR7, (CR10R20)tS(O)mR7, (CR10R20)tNHS(O)2R7, or (CR10R20)tNR4R14; and
wherein the cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic and heterocyclic alkyl moieties may be optionally substituted;R9 is hydrogen, C(Z)R6 or optionally substituted C1-10 alkyl, optionally substituted aryl or optionally substituted aryl-C1-4 alkyl; R10 and R20 are independently selected at each occurrence from hydrogen or C1-4alkyl; R11 is C1-4 alkyl, halo-substituted C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylC1-4 alkyl, heteroaryl, heteroarylC1-4 alkyl, heterocyclyl, heterocyclylC1-4 alkyl, (CR10R20)tOR7, (CR10R20)tS(O)mR7, (CR10R20)tNHS(O)2R7, or (CR10R20)vNR4R14; and
wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclyl, and heterocyclylalkyl moieties may be optionally substituted;v is 0 or an integer having a value of 1 or 2; t is an integer having a value of 1 to 3;
whereinRa′
is C1-4 alkyl, halo-substituted C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylC1-4 alkyl, heteroaryl, heteroarylC1-4alkyl, heterocyclyl, heterocyclyl C1-4 alkyl, (CR10R20)OR7, (CR10R20)vS(O)mR7, (CR10R20)NHS(O)2R7, or (CR10R20)NR4R14, and wherein the aryl, arylalkyl, heteroaryl, and heteroaryl alkyl moieties may be optionally substituted; andZ is oxygen or sulfur.
- , (CR10R20)vC(O)H, SR5, S(O)R5, S(O)2R5, (CR10R20)vOR8, ZC(Z)R11, NR10C(Z)R11, or NR10S(O)2R7; and
-
27. The compound according to claim 18 wherein R1 is a phenyl ring substituted one or more times independently by halogen, alkyl, hydroxy, alkoxy, amino, or halosubstituted alkyl.
-
28. The compound according to claim 26 wherein R1 is an optionally substituted aryl.
-
29. The compound according to claim 28 wherein R1 is an optionally substituted phenyl.
-
30. The compound according to claim 18 wherein R1 is a phenyl ring, substituted one or more times independently by halogen, C1-4 alkyl, or halo-Substituted-C1-4 alkyl.
-
31. The compound according to claim 30 wherein R1 is substituted in the 2,4, or 6-position, di-substituted in the 2,4-position, or tri-substituted in the 2,4,6-position.
-
32. The compound according to claim 31 wherein R1 is 2,4-difluorophenyl, 2-fluorophenyl, 4-fluorophenyl, 2-methyl-4-fluorophenyl, or 2,4,6-trifluorophenyl.
-
33. The compound according to claim 18 wherein R1 is 2-methyl-4-fluorophenyl.
-
34. The compound according to claim 18 wherein Rg is methyl.
-
35. The compound according to claim 18 wherein m is 0 or 2.
-
19. The compound according to claim 18 wherein the R3 ring is optionally substituted one or more times independently by C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylC1-10 alkyl, C5-7 cycloalkenyl, C5-7 cycloalkenyl C1-10 alkyl, halogen, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nNR10S(O)2R7, (CR10R20)nNR4R14, (CR10R20)nCN, (CR10R20)nS(O)2NR4R14, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR4R14, (CR10R20)nNR10C(Z)R6, (CR10R20)nNR10C(═
-
36. A compound of the formula
- View Dependent Claims (37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)
-
37. The compound according to claim 36 wherein R3 is an optionally substituted C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, or aryl.
-
38. The compound according to claim 37 wherein the R3 optional substituents are independently selected from C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylC1-10 alkyl, C5-7 cycloalkenyl, C5-7 cycloalkenyl C1-10 alkyl, halogen, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nNR10S(O)2R7, (CR10R20)nNR4R14, (CR10R20)nCN, (CR10R20)nS(O)2NR4R14, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR4R14, (CR10R20)nNR10C(Z)R6, (CR10R20)nNR10C(═
- NR10)NR4R14, (CR10R20)nOC(Z)NR4R14, (CR10R20)nNR10C(Z) NR4R14, or (CR10R20)nNR10C(Z)OR7; and
R4 and R14 are each independently selected from hydrogen, optionally substituted C1-4 alkyl, optionally substituted C3-7 cycloalkyl, C3-7 cycloalkylC1-4alkyl, optionally substituted aryl, or optionally substituted aryl-C1-4 alkyl, or R4 and R14 together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9; R6 is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl C1-10alkyl, aryl, arylC1-10alkyl, heteroaryl or heteroarylC1-10 alkyl, wherein each of these moieties may be optionally substituted; R7 is a C1-6alkyl, aryl, arylC1-6alkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, or heteroarylC1-6alkyl; and
wherein each of these moieties may be optionally substituted;R9 is hydrogen, C(Z)R6 or optionally substituted C1-10 alkyl, optionally substituted aryl or optionally substituted aryl-C1-4 alkyl; R10 and R20 are independently selected at each occurrence from hydrogen or C1-4alkyl; n is 0 or an integer having a value of 1 to 10; m is 0 or an integer having a value of 1 or 2; Z is oxygen or sulfur.
- NR10)NR4R14, (CR10R20)nOC(Z)NR4R14, (CR10R20)nNR10C(Z) NR4R14, or (CR10R20)nNR10C(Z)OR7; and
-
39. The compound according to claim 38 wherein the R3 optional substituents are independently selected from halogen, alkyl, hydroxy, alkoxy, amino, or halosubstituted alkyl.
-
40. The compound according to claim 38 wherein R3 is an optionally substituted C1-10 alkyl or aryl.
-
41. The compound according to claim 40 wherein R3 is a phenyl ring, substituted one or more times independently by halogen, C1-4 alkyl, or halo-substituted-C1-4 alkyl.
-
42. The compound according to claim 41 wherein the R3 phenyl ring is optionally substituted in the 2, 4, or 6-position, di-substituted in the 2,4-position, or tri-substituted in the 2, 4, 6-position.
-
43. The compound according to claim 36 wherein R3 is a 2-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2-methyl-4-fluorophenyl, or 2,4,6-trifluorophenyl.
-
44. The compound according to claim 43 wherein R3 is a 2,6-difluorophenyl.
-
45. The compound according to claim 36 wherein R1 is an optionally substituted aryl.
-
46. The compound according to claim 45 wherein R1 is a phenyl optionally substituted one or more times independently by halogen, alkyl, hydroxy, alkoxy, amino, or halosubstituted alkyl.
-
47. The compound according to claim 46 wherein the R1 phenyl is substituted in the 2, 4, or 6-position, di-substituted in the 2,4-position, or tri-substituted in the 2, 4, 6-position.
-
48. The compound according to claim 47 wherein R1 is 2,4-difluorophenyl, 2-fluorophenyl, 4-fluorophenyl, 2-methyl-4-fluorophenyl, or 2,4,6-trifluorophenyl.
-
49. The compound according to claim 36 wherein R1 is 2-methyl-4-fluorophenyl.
-
50. The compound according to claim 36 wherein R1 is optionally substituted one or more times, independently, by halogen, C1-4 alkyl, halo-substituted-C1-4 alkyl, cyano, nitro, (CR10R20)vNR4R14, (CR10R20)vC(Z)NR4R14, (CR10R20)vC(Z)OR8, (CR10R20)vCORa′
- , (CR10R20)vC(O)H, SR5, S(O)R5, S(O)2R5, (CR10R20)vOR8, ZC(Z)R11, NR10C(Z)R11, or NR10S(O)2R7; and
R4 and R14 are each independently selected from hydrogen, optionally substituted C1-4 alkyl, optionally substituted C3-7 cycloalkyl, C3-7 cycloalkylC1-4alkyl, optionally substituted aryl, or optionally substituted aryl-C1-4 alkyl, or R4 and R14 together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9; R5 is hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR4R14, excluding the moieties SR5 being SNR4R14, S(O)2R5 being SO2H and S(O)R5 being SOH; R6 is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl C1-10alkyl, aryl, arylC1-10 alkyl, heteroaryl or heteroarylC1-10 alkyl, wherein each of these moieties may be optionally substituted; R7 is a C1-6alkyl, aryl, arylC1-6alkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, or heteroarylC1-6alkyl; and
wherein each of these moieties may be optionally substituted;R8 is hydrogen, C1-4 alkyl, halo-substituted C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylC1-4 alkyl, heteroaryl, heteroarylC1-4 alkyl, heterocyclyl, heterocyclylC1-4 alkyl, (CR10R20)tOR7, (CR10R20)tS(O)mR7, (CR10R20)tNHS(O)2R7, or (CR10R20)tNR4R14; and
wherein the cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic and heterocyclic alkyl moieties may be optionally substituted;R9 is hydrogen, C(Z)R6 or optionally substituted C1-10 alkyl, optionally substituted aryl or optionally substituted aryl-C1-4 alkyl; R10 and R20 are independently selected at each occurrence from hydrogen or C1-4alkyl; R11 is C1-4 alkyl, halo-substituted C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylC1-4 alkyl, heteroaryl, heteroarylC1-4 alkyl, heterocyclyl, heterocyclylC1-4 alkyl, (CR10R20)tOR7, (CR10R20)tS(O)mR7, (CR10R20)tNHS(O)2R7, or (CR10R20)vNR4R14; and
wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclyl, and heterocyclylalkyl moieties may be optionally substituted;v is 0 or an integer having a value of 1 or 2; t is an integer having a value of 1 to 3;
whereinRa′
is C1-4 alkyl, halo-substituted C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylC1-4 alkyl, heteroaryl, heteroarylC1-4alkyl, heterocyclyl, heterocyclyl C1-4 alkyl, (CR10R20)vOR7, (CR10R20)vS(O)mR7, (CR10R20)vNHS(O)2R7, or (CR10R20)vNR4R14, and wherein the aryl, arylalkyl, heteroaryl, and heteroaryl alkyl moieties may be optionally substituted; andZ is oxygen or sulfur.
- , (CR10R20)vC(O)H, SR5, S(O)R5, S(O)2R5, (CR10R20)vOR8, ZC(Z)R11, NR10C(Z)R11, or NR10S(O)2R7; and
-
51. The compound according to claim 50 wherein R1 is an optionally substituted phenyl.
-
52. The compound according to claim 36 wherein R12 is a C1-10 alkyl.
-
53. The compound according to claim 36 wherein Rg is methyl.
-
54. The compound according to claim 36 wherein m is 0 or 2.
-
55. The compound according to claim 38 wherein the R3 is an aryl ring optionally substituted one or more times independently by C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylC1-10 alkyl, C5-7 cycloalkenyl, C5-7 cycloalkenyl C1-10 alkyl, halogen, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)n NR10S(O)2R7, (CR10R20)nNR4R14, (CR10R20)nCN, (CR10R20)nS(O)2NR4R14, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR4R14, (CR10R20)nNR10C(Z)R6, (CR10R10)nNR10C(═
- NR10)NR4R14, (CR10R20)nOC(Z)NR4R14, (CR10R20)nNR10C(Z)NR4R14, or (CR10R20)nNR10C(Z)OR7; and
R4 and R14 are each independently selected from hydrogen, optionally substituted C1-4 alkyl, optionally substituted C3-7 cycloalkyl, C3-7 cycloalkylC1-4alkyl, optionally substituted aryl, or optionally substituted aryl-C1-4 alkyl, or R4 and R14 together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9; R6 is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl C1-10alkyl, aryl, arylC1-10 alkyl, heteroaryl or heteroarylC1-10 alkyl, wherein each of these moieties may be optionally substituted; R7 is a C1-6alkyl, aryl, arylC1-6alkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, or heteroarylC1-6alkyl; and
wherein each of these moieties may be optionally substituted;R9 is hydrogen, C(Z)R6 or optionally substituted C1-10 alkyl, optionally substituted aryl or optionally substituted aryl-C1-4 alkyl; R10 and R20 are independently selected at each occurrence from hydrogen or C1-4alkyl; n is 0 or an integer having a value of 1 to 10; m is 0 or an integer having a value of 1 or 2; Z is oxygen or sulfur.
- NR10)NR4R14, (CR10R20)nOC(Z)NR4R14, (CR10R20)nNR10C(Z)NR4R14, or (CR10R20)nNR10C(Z)OR7; and
-
37. The compound according to claim 36 wherein R3 is an optionally substituted C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, or aryl.
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeGlaxoSmithKline LLC (GSK plc)
-
Original AssigneeGlaxoSmithKline LLC (GSK plc)
-
InventorsHall, Ralph, Jin, Qi, Kasparec, Jiri, Boehm, Jeffrey C., Silva, Domingos J., Adams, Jerry L., Taggart, John J.
-
Primary Examiner(s)COLEMAN, BRENDA LIBBY
-
Application NumberUS11/839,830Publication NumberTime in Patent Office1,069 DaysField of Search544/317US Class Current544/317CPC Class CodesA61P 1/00 Drugs for disorders of the ...A61P 1/04 for ulcers, gastritis or re...A61P 1/18 for pancreatic disorders, e...A61P 11/00 Drugs for disorders of the ...A61P 11/06 AntiasthmaticsA61P 13/12 of the kidneysA61P 17/00 Drugs for dermatological di...A61P 17/02 for treating wounds, ulcers...A61P 17/04 AntipruriticsA61P 17/06 AntipsoriaticsA61P 19/00 Drugs for skeletal disordersA61P 19/02 for joint disorders, e.g. a...A61P 19/06 Antigout agents, e.g. antih...A61P 19/08 for bone diseases, e.g. rac...A61P 19/10 for osteoporosisA61P 21/00 Drugs for disorders of the ...A61P 25/00 Drugs for disorders of the ...A61P 27/02 Ophthalmic agentsA61P 27/16 OtologicalsA61P 29/00 Non-central analgesic, anti...A61P 3/10 : for hyperglycaemia, e.g. an...A61P 31/00 : Antiinfectives, i.e. antibi...A61P 31/04 : Antibacterial agentsA61P 31/12 : AntiviralsA61P 31/14 : for RNA virusesA61P 31/16 : for influenza or rhinovirusesA61P 35/00 : Antineoplastic agentsA61P 35/04 : specific for metastasisA61P 37/06 : Immunosuppressants, e.g. dr...A61P 43/00 : Drugs for specific purposes...A61P 7/00 : Drugs for disorders of the ...A61P 7/02 : Antithrombotic agents; Anti...A61P 9/00 : Drugs for disorders of the ...A61P 9/04 : Inotropic agents, i.e. stim...A61P 9/10 : for treating ischaemic or a...C07D 239/47 : One nitrogen atom and one o...C07D 471/04 : Ortho-condensed systems